Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04584710 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
A Phase 2 study of COVID-19, sponsored by Restorbio.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04584710: Active Phase 2 study of COVID-19, sponsored by Restorbio.
NCT04584710 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by Restorbio. The registered enrollment target is 60 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04584710, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by Restorbio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Primary Outcome
The number of days from the date of receipt of a positive SARS-CoV-2 swab test result to the date of first dose of study drug in asymptomatic subjects who: * have SARS-CoV-2 detected on a surveillance nasal or nasopharyngeal swab OR * live in the same house or apartment as someone who has laboratory-confirmed symptomatic COVID-19
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RTB101
Study Locations (2)
Connecticut
- University of Connecticut, UConn Center on Aging - Farmington
Massachusetts
- Hebrew Senior Life, Marcus Institute for Aging Research - Roslindale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-02 |
| Phase | Phase 2 |
What the registry record for NCT04584710 still lists
NCT04584710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04584710 reports a single indexed study location in Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04584710 about?
NCT04584710 is a clinical study titled "A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults". The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
What is the current status of trial NCT04584710?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-10-13. Estimated completion is 2021-02.
What conditions does trial NCT04584710 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04584710?
The interventions under investigation include: Placebo (DRUG), RTB101 (DRUG).
Who is sponsoring clinical trial NCT04584710?
This trial is sponsored by Restorbio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04584710 being conducted?
This trial has 2 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04584710's enrollment target sits among peer trials
60 233rd of 298 higher than 60 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI